{"url_path":"/sec/rgbpp/10-q/2026/item-4","section_key":"item-4","section_title":"Item 4 Controls and Procedures.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1589150/0001493152-26-022924-index.html","accession_number":"0001493152-26-022924","cik":"0001589150","ticker":"RGBP","issuer_name":"Regen BioPharma Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1589150/0001493152-26-022924-index.html","primary_entity_key":"0001589150","primary_entity_name":"Regen BioPharma Inc"},"word_count":201,"has_tables":true,"body_markdown":"**Item\n4. Controls and Procedures.**\n\n \n\n**Evaluation\nof Disclosure Controls and Procedures**\n\n** **\n\nAs\nof the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation\nof David Koos, who is the Company’s Principal Executive Officer and Principal Financial Officer of the effectiveness of the design\nand operation of the Company’s disclosure controls and procedures. The Company’s disclosure controls and procedures are designed\nto provide a reasonable level of assurance of achieving the Company’s disclosure control objectives. The Company’s Principal\nExecutive Officer and Principal Financial Officer have concluded that the Company’s disclosure controls and procedures were ineffective\nat this reasonable assurance level as of the period covered.\n\n \n\n**Changes\nin Internal Controls over Financial Reporting**\n\n** **\n\nIn\nconnection with the evaluation of the Company’s internal controls during the period commencing on January 1, 2026 and ending on\nMarch 31, 2026, David Koos, who serves as the Company’s Principal Executive Officer , Principal Financial Officer has determined\nthat there were no changes to the Company’s internal controls over financial reporting that have been materially affected, or is\nreasonably likely to materially effect, the Company’s internal controls over financial reporting.\n\n \n\n23\n\n \n\n \n\n**PART\nII - OTHER INFORMATION**"}